Action on Hearing Loss Logo
    Total results:
    Search
      Total results:

      Drug to reduce hearing loss due to cancer treatments is now available

      Some cancer survivors develop hearing loss, caused by the drugs that treat cancer. A US-based company, Fennec Pharmaceuticals, have developed a new drug that prevents hearing loss in children who have been treated for liver cancer. Dr Carina Santos, from our research team, tells us more.

      By: Carina Santos | 20 November 2017

      Cancer is a devastating disease but for some people, surviving cancer does not always mean going back to a normal life. Some cancer survivors have to face a life with severe hearing loss caused by their life-saving chemotherapy. The consequences of hearing loss can be particularly devastating in children, impacting on their language and social development.

      Cisplatin is a platinum-based compound widely used in chemotherapy treatments, especially in children‘s cancers because it is highly effective - 80% survival rates. However, this drug can lead to permanent and severe high frequency hearing loss in 6 out of every 10 children following treatment. Hearing loss can occur within hours or days after the first cycle of cisplatin treatment, or develop after repeated rounds of treatment. Many of these children will require hearing aids or cochlear implants for the rest of their lives. However, the adaptation of a child to hearing aids is not easy and a lot of them end up not using them properly. (For real testimonies of mothers dealing with the hearing loss of their children after cancer treatment please watch here and here)

      Fennec Pharmaceuticals is a US-based pharmaceutical company that is developing a drug (Sodium Thiosulfate (STS)) to reduce cisplatin-induced hearing loss in children.  They recently presented their results from Phase III clinical trials – the final stage of clinical testing before a drug is approved for use. The results show that 67% of children with standard risk hepatoblastoma (a type of liver cancer) treated with cisplatin developed hearing loss, compared to just 37% of children that were treated with cisplatin + STS. Fennec pharmaceuticals has also shown that if STS is given 6 hours after cisplatin treatment it could still help protect hearing without interfering with cisplatin’s ability to kill cancer (you can watch Dr. Penelope Brock, MD, of Great Ormond Street Hospital in London, UK, explaining the results here).

      Fennec Pharmaceuticals will now apply for a license from the Food and Drug Administration in the USA and the European Medicines Agency so that they can market and sell the drug they have developed. In the meantime, before it is licensed, parents of children with hepatoblastoma undergoing chemotherapy who wish to protect their children’s hearing with STS can access it under a special scheme called the Named Patient Programme, also known as Compassionate Use Program. These are programmes created by regulators to allow patients with an unmet medical need to have access to promising drugs that are in late-stages of development before they have been approved. You can find out more information about this drug and its Named Patient Programme in the links below.

      To see more about STS please consult Fennec Pharmaceuticals webpage: http://fennecpharma.com/

      Press release of clinical trials results: http://fennecpharma.com/fennec-announces-positive-results-from-phase-3-siopel-6-study-on-pedmark-sodium-thiosulfate-presented-at-the-49th-congress-of-the-international-society-of-pediatric-oncology-siop-2017-mee/

      STS Named Patient Programme: http://fennecpharma.com/fennec-announces-launch-of-european-named-patient-programme-for-sodium-thiosulfate-for-pediatric-patients-with-standard-risk-hepatoblastoma/

      Recent Posts

      EE partnership brings unbeatable packages

      For the first time ever, selected mobile phones with EE Pay As You Go plans, tailored for people who are deaf or have hearing loss, are available from Action on Hearing Loss.

      By: Brian Burns
      17 October 2018

      REGAIN update on the progress so far and a further opportunity for people with hearing loss to take part in the trial

      A team of researchers and clinicians at UCL’s Ear Institute and the Royal National Throat Nose and Ear Hospital are delighted to announce that the REGAIN trial is approaching its first anniversary and are continuing to recruit people with hearing loss to participate in a ground breaking clinical trial to test the safety and efficacy of a new drug that aims to treat sensorineural hearing loss. The criteria for eligibility to participate in the trial has recently been broadened to include participants with hearing loss of up to 20 years duration (see below for further information).

      By: REGAIN
      16 October 2018

      Preventing hearing loss: the search for treatments

      Medicines like aminoglycoside antibiotics or cisplatin are used to combat life-threatening infections and cancer, respectively, but their use may come at the price of someone’s hearing. Several treatments to prevent the loss of hearing caused by these medicines are currently being developed. Our Translational Research Manager, Dr Carina Santos, tells us more.

      By: Dr Carina Santos
      12 October 2018

      Shining a light on the cochlea

      We fund research across the globe into treatments for hearing loss and tinnitus. One of our newest projects, at the Bionics Institute in Australia, is investigating if we can improve how well cochlear implants work using light.

      By: Dr Tracey Pollard
      11 October 2018